stars 1 stars 2 stars 3

生产优良的医疗器械 爱湃斯生物科技股份有限公司致力于研发并生产优良的医疗器材,爱湃斯的产品线完整,包含骨科固定、骨科矫正、及骨头和软组织再生所需要的器材、植入物和生物材料。 外科医疗器材的领导者 爱湃斯生物科技股份有限公司将是未来外科医疗器材的领导者。在我们不断的开发更好的产品下,我们保证产品的高品质与不断的创新与研发,在市场上奠定了优良的基础,我们的目标是提供病患最安全,最先进的植入物,器材以及相关科技,以确保安全可靠的手术步骤,使病人快速的痊愈和手术后无病痛的人生。 创新外科技术 爱湃斯生物科技股份有限公司和医院的外科医师密切合作,并与科学家,电机,机械专家所组成的产品研发小组共同研究创新外科技术与产品,以确保病患的福祉。 信心、谨慎和坚持 爱湃斯生物科技股份有限公司的英文为Aplus,它的中文则代表不断的创新从事研究、开发、临床测试与调查和致力于骨折以及相关疾病治疗的教育。 爱湃斯生物科技股份有限公司在每一样新产品上市之前,都有临床研究报告可以证明产品的性能和品质。因为爱湃斯对新器材和新植入物的细心,谨慎与坚持。 成长于茁壮 爱湃斯仍不断成长与茁壮,希望能带给医生更好技术与医疗器材并造福更多伤患

APlus Bio Questions

The APlus Bio annual revenue was $202000 in 2026.

Dennis Wu is the CEO of APlus Bio.

12 people are employed at APlus Bio.

The NAICS codes for APlus Bio are [325, 32, 3254].

The SIC codes for APlus Bio are [28, 80, 283].

Top APlus Bio Employees

View Similar People
Learn More
How It Works
get free account
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups.
search page
Search the #1 Contact Database
Get contact details of over 700M profiles across 60M companies – all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
get contact page
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users